Marshall Wace, LLP Kamada LTD Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$5.43 - $6.81 $59,979 - $75,223	-11,046 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.21 - $6.82 $57,549 - $75,333	11,046 New	11,046 $73,000
Q2 2021 Aug 13, 2021	SELL	$5.67 - $6.33 $65,737 - $73,390	-11,594 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.02 - $8.06 $328,559 - $439,898	-54,578 Reduced 82.48%	11,594 $71,000
Q4 2020 Feb 16, 2021	SELL	$6.3 - $8.46 $23,108 - $31,031	-3,668 Reduced 5.25%	66,172 $427,000
Q3 2020 Nov 16, 2020	SELL	$8.02 - $11.73 $99,937 - $146,167	-12,461 Reduced 15.14%	69,840 $596,000
Q2 2020 Aug 13, 2020	SELL	$5.37 - $9.45 $58,285 - $102,570	-10,854 Reduced 11.65%	82,301 $630,000
Q1 2020 May 15, 2020	BUY	$4.56 - $7.13 $48,833 - $76,355	10,709 Added 12.99%	93,155 $561,000
Q4 2019 Feb 14, 2020	BUY	$4.97 - $7.7 $267,897 - $415,053	53,903 Added 188.85%	82,446 $565,000
Q3 2019 Nov 14, 2019	SELL	$5.11 - $5.99 $273,282 - $320,345	-53,480 Reduced 65.2%	28,543 $147,000
Q2 2019 Aug 14, 2019	BUY	$5.39 - $6.26 $181,659 - $210,980	33,703 Added 69.75%	82,023 $450,000
Q1 2019 May 14, 2019	BUY	$5.12 - $6.18 $247,398 - $298,617	48,320 New	48,320 $276,000

6.48M

200

Ticker KMDA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 44,800,500
Market Cap $264M
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.